---
title: "AI-guided nanoparticle therapeutics for infectious diseases integrating CRISPR, phage hybrids, and"
id: "pubmed-43037917"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-43037917"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/43037917/"
doi: "10.1186/s11671-026-05108-1"
published_at: "2026-11-16T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# AI-guided nanoparticle therapeutics for infectious diseases integrating CRISPR, phage hybrids, and
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-43037917
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/43037917/)
- **DOI:** [10.1186/s11671-026-05108-1](https://doi.org/10.1186%2Fs11671-026-05108-1)
- **Published At:** 2026-11-16T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Review article synthesizing preclinical literature on **nanoparticle therapeutics** for infectious diseases, with emphasis on integrated modalities including computational design, gene-editing delivery, phage hybrids, and host immune modulation. - Investigators reported that **AI-guided modelling** can predict and optimize nanoparticle physicochemical properties — for example size, surface charge, and protein decoration — to improve pathogen targeting and formulation stability. - The authors noted nanoparticles act as protective carriers for **CRISPR**-Cas cargo, shielding nucleic acids from enzymatic degradation and enabling targeted intracellular delivery via pH-responsive endosomal escape mechanisms. - Data indicated tissue-targeted delivery and infection-site specificity could enable genome editing to reverse antimicrobial resistance in pathogens such as HIV and Mycobacterium tuberculosis, according to the review. - The review described **bacteriophage therapy** coupled to nanoparticles (phage–nanoparticle hybrids) as a strategy that can enhance phage stability, delivery efficiency, and potentially broaden host range. - Authors observed engineered nanoparticles can either suppress hyperinflammation or stimulate immune responses, depending on design, to aid pathogen clearance or limit host damage. - The study team highlighted translational barriers: large-scale manufacturing, scalability, reproducibility, regulatory uncertainty with scarce precedents, safety and efficacy concerns, unpredictable host–phage interactions, cost-effectiveness, and equitable access. - Clinical trial registration: Not applicable; this manuscript is a review and does not report original clinical trials or new human/animal experimental data.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/43037917/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43037917%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/43037917/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/43037917/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/43037917/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/43037917/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/43037917/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/43037917/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43037917%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43037917%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/43037917/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43037917/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43037917/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/43037917/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43037917/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/43037917/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/43037917/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/43037917/#conflict-of-interest) * [ References ](https://pubmed.ncbi.nlm.nih.gov/43037917/#references) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/43037917/#publication-types) Title & authors Abstract Conflict of interest statement References Publication types Review Discov Nano Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Discov+Nano%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Discov+Nano%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43037917/) . 2026 Nov 16;21(1):644. doi: 10.1186/s11671-026-05108-1. # Nanoparticle therapeutics for infectious diseases integrating AI-guided design, crispr delivery, phage synergy, and immune modulation [Muhammad Shahid Mehmood](https://pubmed.ncbi.nlm.nih.gov/?term=Mehmood+MS&cauthor_id=43037917)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#full-view-affiliation-1 "University of Agriculture Faisalabad, Faisalabad, 38000, Pakistan."), [Fariha Javaid](https://pubmed.ncbi.nlm.nih.gov/?term=Javaid+F&cauthor_id=43037917)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#full-view-affiliation-2 "University of the Punjab, Lahore, Pakistan."), [Eeman Afroz](https://pubmed.ncbi.nlm.nih.gov/?term=Afroz+E&cauthor_id=43037917)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#full-view-affiliation-3 "Allama Iqbal Medical College, Lahore, Pakistan."), [Muhammad Saleem](https://pubmed.ncbi.nlm.nih.gov/?term=Saleem+M&cauthor_id=43037917)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#full-view-affiliation-4 "Kohsar University, Murree, Pakistan."), [Hikmat Ullah](https://pubmed.ncbi.nlm.nih.gov/?term=Ullah+H&cauthor_id=43037917)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#full-view-affiliation-5 "University of Chinese Academy of Sciences, Beijing, 100049, China."), [Amir Majdi Moh'd](https://pubmed.ncbi.nlm.nih.gov/?term=Moh%27d+AM&cauthor_id=43037917)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#full-view-affiliation-6 "Yarmouk University, Irbid, Jordan."), [Iqra Shahid](https://pubmed.ncbi.nlm.nih.gov/?term=Shahid+I&cauthor_id=43037917)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#full-view-affiliation-1 "University of Agriculture Faisalabad, Faisalabad, 38000, Pakistan."), [Mohammad Jalal Nazari](https://pubmed.ncbi.nlm.nih.gov/?term=Nazari+MJ&cauthor_id=43037917)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#full-view-affiliation-7 "Kateb University, Kabul, Afghanistan. jalalnazari331@gmail.com.") Affiliations Expand ### Affiliations * 1 University of Agriculture Faisalabad, Faisalabad, 38000, Pakistan. * 2 University of the Punjab, Lahore, Pakistan. * 3 Allama Iqbal Medical College, Lahore, Pakistan. * 4 Kohsar University, Murree, Pakistan. * 5 University of Chinese Academy of Sciences, Beijing, 100049, China. * 6 Yarmouk University, Irbid, Jordan. * 7 Kateb University, Kabul, Afghanistan. jalalnazari331@gmail.com. * PMID: **43037917** * DOI: [ 10.1186/s11671-026-05108-1 ](https://doi.org/10.1186/s11671-026-05108-1) Item in Clipboard Review # Nanoparticle therapeutics for infectious diseases integrating AI-guided design, crispr delivery, phage synergy, and immune modulation Muhammad Shahid Mehmood et al. Discov Nano. 2026. Show details Display options Display options Format Abstract PubMed PMID Discov Nano Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Discov+Nano%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Discov+Nano%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43037917/) . 2026 Nov 16;21(1):644. doi: 10.1186/s11671-026-05108-1. ### Authors [Muhammad Shahid Mehmood](https://pubmed.ncbi.nlm.nih.gov/?term=Mehmood+MS&cauthor_id=43037917)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#short-view-affiliation-1 "University of Agriculture Faisalabad, Faisalabad, 38000, Pakistan."), [Fariha Javaid](https://pubmed.ncbi.nlm.nih.gov/?term=Javaid+F&cauthor_id=43037917)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#short-view-affiliation-2 "University of the Punjab, Lahore, Pakistan."), [Eeman Afroz](https://pubmed.ncbi.nlm.nih.gov/?term=Afroz+E&cauthor_id=43037917)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#short-view-affiliation-3 "Allama Iqbal Medical College, Lahore, Pakistan."), [Muhammad Saleem](https://pubmed.ncbi.nlm.nih.gov/?term=Saleem+M&cauthor_id=43037917)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#short-view-affiliation-4 "Kohsar University, Murree, Pakistan."), [Hikmat Ullah](https://pubmed.ncbi.nlm.nih.gov/?term=Ullah+H&cauthor_id=43037917)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#short-view-affiliation-5 "University of Chinese Academy of Sciences, Beijing, 100049, China."), [Amir Majdi Moh'd](https://pubmed.ncbi.nlm.nih.gov/?term=Moh%27d+AM&cauthor_id=43037917)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#short-view-affiliation-6 "Yarmouk University, Irbid, Jordan."), [Iqra Shahid](https://pubmed.ncbi.nlm.nih.gov/?term=Shahid+I&cauthor_id=43037917)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#short-view-affiliation-1 "University of Agriculture Faisalabad, Faisalabad, 38000, Pakistan."), [Mohammad Jalal Nazari](https://pubmed.ncbi.nlm.nih.gov/?term=Nazari+MJ&cauthor_id=43037917)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/43037917/#short-view-affiliation-7 "Kateb University, Kabul, Afghanistan. jalalnazari331@gmail.com.") ### Affiliations * 1 University of Agriculture Faisalabad, Faisalabad, 38000, Pakistan. * 2 University of the Punjab, Lahore, Pakistan. * 3 Allama Iqbal Medical College, Lahore, Pakistan. * 4 Kohsar University, Murree, Pakistan. * 5 University of Chinese Academy of Sciences, Beijing, 100049, China. * 6 Yarmouk University, Irbid, Jordan. * 7 Kateb University, Kabul, Afghanistan. jalalnazari331@gmail.com. * PMID: **43037917** * DOI: [ 10.1186/s11671-026-05108-1 ](https://doi.org/10.1186/s11671-026-05108-1) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Infectious diseases continue to pose a global health challenge, intensified by antimicrobial resistance and limitations of pharmaceutical countermeasures. Nanotechnology offers a promising front against these barriers using intelligent, multifunctional systems. This review explores the convergence of Artificial Intelligence (AI), CRISPR gene editing, bacteriophage therapy, and immune modulation within the framework of second-generation nanoparticle therapeutics. AI-guided modelling enables predictive optimization of nanoparticle design on the basis of size, charge, and surface proteins, targeting specific pathogens and providing enhanced stability. Consequently, nanoparticles serve as precision nanocarriers and protective delivery vehicles for the CRISPR-Cas system, shielding nucleic acid cargo from enzymatic degradation and enabling targeted intracellular delivery via pH-responsive endosomal escape mechanisms. The nanoparticles not only provide protection but also enable tissue-targeting and infection-site-specific delivery of the CRISPR-Cas system, facilitating precise genome editing to reverse resistance in specific pathogens such as HIV and Mycobacterium tuberculosis. Phage nanoparticle hybrids further expand antimicrobial potency by enhancing phage stability, delivery, and host range. Moreover, engineered nanoparticles modulate the immune system via immunosuppressive and immunostimulant strategies for reducing hyperinflammation and enhancing pathogen clearance, respectively. Despite such encouraging laboratory outcomes, the clinical translation of AI-integrated nanoparticle platforms still faces a number of obstacles. Large-scale manufacturing, scalability, and reproducibility pose a significant challenge. Regulatory approvals for such multi-modal nano-drugs seem to get bogged down due to vague and scarce exemplary proofs. Furthermore, safety and efficacy apprehensions, unpredictable and complex host-phage interactions, cost-effectiveness, and equitable access remain a subject matter of concern. Conclusively, the convergence of advanced nanotechnology, artificial intelligence, and synthetic biology marks the dawn of a transformative era in infectious disease therapeutics where treatment is not only intelligent and adaptive but also ethically and globally inclusive.Clinical trial registrationNot applicable. **Keywords:** AI-guided nanomedicine; Antimicrobial resistance; Bacteriophage therapy; CRISPR delivery systems; Immune modulation; Infectious diseases; Nanoparticle therapeutics. © 2026. The Author(s). [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declarations. Ethical Approval: Not applicable. This manuscript is a review article based entirely on previously published literature and does not involve human participants, animal subjects, or any original experimental work requiring ethical approval. Consent to Participate: Not applicable. Consent to Publish: All authors have read and approved the final version of the manuscript and consent to its publication. Use of Generative AI and AI-Assisted Technologies: AI-assisted tools were used solely for grammatical corrections and language refinement during the preparation of this manuscript. No AI tools or technologies were used for data generation, analysis, interpretation, or any substantive content creation. Competing interests: The authors declare no competing interests. ## References 1. 1. Saravanan H, Subramani T, Rajaramon S, et al. Exploring nanocomposites for controlling infectious microorganisms: charting the path forward in antimicrobial strategies. Front Pharmacol. 2023;14:1282073. - [PubMed](https://pubmed.ncbi.nlm.nih.gov/37829306/) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/10565656/) 2. 1. AlQurashi DM, AlQurashi TF, Alam RI, et al. Advanced Nanoparticles in Combating Antibiotic Resistance: Current Innovations and Future Directions. J Nanotheranostics. 2025;6:9. 3. 1. Oliveira M, Antunes W, Mota S, et al. An Overview of the Recent Advances in Antimicrobial Resistance. Microorganisms. 2024;12:1920. - [PubMed](https://pubmed.ncbi.nlm.nih.gov/39338594/) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/11434382/) 4. 1. Elshobary ME, Badawy NK, Ashraf Y, et al. Combating Antibiotic Resistance: Mechanisms, Multidrug-Resistant Pathogens, and Novel Therapeutic Approaches: An Updated Review. Pharmaceuticals. 2025;18:402. - [PubMed](https://pubmed.ncbi.nlm.nih.gov/40143178/) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/11944582/) 5. 1. Saffari Natanzi A, Poudineh M, Karimi E, et al. Innovative approaches to combat antibiotic resistance: integrating CRISPR/Cas9 and nanoparticles against biofilm-driven infections. BMC Med. 2025;23:486. - [DOI](https://doi.org/10.1186/s12916-025-04323-4) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/40830872/) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/12366227/) Show all 105 references ## Publication types * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43037917/) [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM **Send To** * [Clipboard](https://pubmed.ncbi.nlm.nih.gov/43037917/) * [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43037917%2F%23open-email-panel) * [Save](https://pubmed.ncbi.nlm.nih.gov/43037917/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43037917%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43037917%2F%23open-collections-panel) * [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/43037917/) [x] NCBI Literature Resources [MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited. Follow NCBI [ Twitter ](https://twitter.com/ncbi) [ Facebook ](https://www.facebook.com/ncbi.nlm) [ LinkedIn ](https://www.linkedin.com/company/ncbinlm) [ GitHub ](https://github.com/ncbi) [ ](https://ncbiinsights.ncbi.nlm.nih.gov/) [Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html) * [ Twitter ](https://twitter.com/NLM_NIH) * [ SM-Facebook ](https://www.facebook.com/nationallibraryofmedicine) * [ SM-Youtube ](https://www.youtube.com/user/NLMNIH) National Library of Medicine [8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323) [Web Policies](https://www.nlm.nih.gov/web_policies.html) [FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office) [HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html) [Help](https://support.nlm.nih.gov/?pagename=pubmed%3Apubmed%3Aabstract%3ANONE) [Accessibility](https://www.nlm.nih.gov/accessibility.html) [Careers](https://www.nlm.nih.gov/careers/careers.html) * [NLM](https://www.nlm.nih.gov/) * [NIH](https://www.nih.gov/) * [HHS](https://www.hhs.gov/) * [USA.gov](https://www.usa.gov/) ![](https://pubmed.ncbi.nlm.nih.gov/stat?HTTP_REFERER=&SELF_URL=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43037917%2F&browserheight=600&browserwidth=1080&colorDepth=24&connection_effectivetype=4g&connection_type=&cookieSize=637&cookieenabled=true&is_browser_supported=true&jsevent=render&jsloadtime=&jsperf_basePage=56&jsperf_connect=0&jsperf_dns=0&jsperf_navTimingNetworkMS=699&jsperf_navTimingRedirectCount=0&jsperf_
## Related Clinical Research

- [Impact of loss to follow-up on 5-year mortality after tuberculosis treatment in São Paulo, Brazil](https://medichelpline.com/clinical-feed/plos-medicine-0-loss-to-follow-up-during-tuberculosis-treatment-and-5-year-mortality-in-brazil.md)
- [Bayesian latent class analysis of pediatric tuberculosis diagnostics in Kenya](https://medichelpline.com/clinical-feed/medrxiv-10-using-bayesian-latent-class-models-to-evaluate-tuberculosis-diagnostics-in-a.md)
- [Viral suppression after test-and-treat in Ethiopia: rates and predictors in Shashemene cohort](https://medichelpline.com/clinical-feed/plos-one-21-viral-suppression-among-adolescents-and-adults-living-with-human.md)
- [Helicobacter pylori Serology and Resistant Hypertension: South African Cohort Protocol](https://medichelpline.com/clinical-feed/plos-one-20-protocol-for-investigating-the-association-between-helicobacter-pylori-exposure.md)
- [AI detection of pulmonary tuberculosis on chest X‑ray: meta-analysis of clinical cohort accuracy](https://medichelpline.com/clinical-feed/medrxiv-12-artificial-intelligence-for-pulmonary-tuberculosis-detection-on-chest-x-ray.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.